Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium
October 12 2021 - 7:00AM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing precision T cell therapies to
treat solid tumors, today announced that it has joined the Northern
Alliance for Advanced Therapies Treatment Centre (NA-ATTC)
consortium. The NA-ATTC consortium is funded by Innovate UK, the
government’s innovation agency, and is one of only three Advanced
Therapy Treatment Centres in the UK.
NA-ATTC was created to address the unique and
complex challenges of bringing pioneering advanced therapy
medicinal products to patients. Specifically, the consortium
focuses on all elements of the clinical delivery pathway from
procurement of starting materials, through to delivery of clinical
trials, and adoption and reimbursement across a range of advanced
therapies and indications.
“We are delighted to join the
Northern Alliance, part of the Advanced Therapy Treatment Centre
network, and contribute to this great initiative focusing on
multiple aspects of operational delivery,” commented Dr
Shree Patel, SVP, Clinical Operations at Achilles. “We
look forward to collaborating and contributing our learnings to the
consortium as we work together for the benefit of patients to
overcome some of the challenges of cell therapy.”
As an industry partner, Achilles will contribute
its knowledge and expertise in supply chain and operations for cell
therapies that has been developed with its precision clonal
neoantigen-reactive T cell therapy (cNeT). Achilles will help the
consortium understand the operational gaps in current pathways and
practices to be bridged to improve delivery of this type of cell
therapy product to patients.
About Achilles
TherapeuticsAchilles is a clinical-stage biopharmaceutical
company developing precision T cell therapies targeting clonal
neoantigens: protein markers unique to the individual that are
expressed on the surface of every cancer cell. The Company has two
ongoing Phase I/IIa trials, the CHIRON trial in patients with
unresectable locally advanced and metastatic non-small cell lung
cancer (NSCLC) and the THETIS trial in patients with recurrent or
metastatic melanoma. Achilles uses DNA sequencing data from each
patient, together with its proprietary PELEUS™ bioinformatics
platform, to identify clonal neoantigens specific to that patient,
and then develop precision T cell-based product candidates
specifically targeting those clonal neoantigens.
About NA-ATTCThe NA-ATTC,
formally established in March 2018, is a consortium of industry,
NHS and academic organisations led by Newcastle upon Tyne Hospitals
NHS Foundation Trust and the Scottish National Blood Transfusion
Service (SNBTS). The purpose of the centre is to develop the
systems and infrastructure required to support the delivery of cell
and gene therapies with the ultimate aim of increasing patient
access to advanced therapy medicinal products (ATMPs) on a national
level.
For a complete list of partners, please visit:
https://www.theattcnetwork.co.uk/centres/northern-alliance/.
Forward-Looking StatementsThis
press release contains express or implied forward-looking
statements that are based on our management's belief and
assumptions and on information currently available to our
management. Although we believe that the expectations reflected in
these forward-looking statements are reasonable, these statements
relate to future events or our future operational or financial
performance, and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Further information:
Lee M. Stern – VP, IR & External
Communications+1 (332)
373-2634l.stern@achillestx.com
Consilium Strategic
CommunicationsMary-Jane Elliott, Sukaina Virji, Melissa
Gardiner+44 (0) 203 709 5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Oct 2023 to Oct 2024